[1] Hettmer S, Li Z, Billin AN, et al.Rhabdomyosarcoma: current challenges and their implications for developing therapies[J]. Cold Spring Harb Perspect Med, 2014, 4(11): a025650. [2] Hicks J, Flaitz C.Rhabdomyosarcoma of the head and neck in children[J]. Oral Oncol, 2002, 38(5): 450-459. [3] Sultan I, Qaddoumi I, Yaser S, et al.Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2 600 patients[J]. J Clin Oncol, 2009, 27(20): 3391-3397. [4] Rodeberg DA, Garcia-Henriquez N, Lyden ER, et al.Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group[J]. J Clin Oncol, 2011, 29(10): 1304-1311. [5] Meza JL, Anderson J, Pappo AS, et al.Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies Ⅲ and Ⅳ: the Children's Oncology Group[J]. J Clin Oncol, 2006, 24(24): 3844-3851. [6] Turner JH, Richmon JD.Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data[J]. Otolaryngol Head Neck Surg, 2011, 145(6): 967-973. [7] Zevallos JP, Jain K, Roberts D, et al.Modern multimodality therapy for pediatric nonorbital parameningeal sarcomas[J]. Head Neck, 2010, 32(11): 1501-1505. [8] Bisogno G, De Salvo GL, Bergeron C, et al.Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2019, 20(11): 1566-1575. [9] Slemmons KK, Yeung C, Baumgart JT, et al.Targeting Hippo-dependent and Hippo-independent YAP1 signaling for the treatment of childhood rhabdomyosarcoma[J]. Cancer Res, 2020, 80(14): 3046-3056. [10] Vassiliou LV, Lalabekyan B, Jay A, et al.Head and neck sarcomas: a single institute series[J]. Oral Oncol, 2017, 65(1): 16-22. [11] Li W, Lu H, Wang D.Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series[J]. J Cancer Res Clin Oncol, 2019, 145(11): 2793-2802. [12] Radzikowska J, Kukwa W, Kukwa A, et al.Management of pediatric head and neck rhabdomyosarcoma: a case-series of 36 patients[J]. Oncol Lett, 2016, 12(5): 3555-3562. [13] Iatrou I, Theologie-Lygidakis N, Schoinohoriti O, et al.Rhabdomyosarcoma of the maxillofacial region in children and adolescents: report of 9 cases and literature review[J]. J Craniomaxillofac Surg, 2017, 45(6): 831-838. [14] Owosho AA, Brady P, Wolden SL, et al.Long-term effect of chemo-intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients[J]. Pediatr Hematol Oncol, 2016, 33(6): 383-392. [15] Vasiwala R, Burud I, Lum SK, et al.Embryonal rhabdomyosarcoma of the middle ear presenting with aural polyp and facial nerve palsy[J]. Med J Malaysia, 2015, 70(5): 314-315. [16] Mazeron R, Oberlin O, Dumas I, et al.Brachytherapy in children with rhabdomyosarcomas of the nasolabial fold[J]. Pediatr Blood Cancer, 2014, 61(7): 1162-1167. [17] Owosho AA, Huang SC, Chen S, et al.A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-Mutant sclerosing are associated with unfavorable outcome[J]. Oral Oncol, 2016, 61(1): 89-97. [18] Sanghvi S, Misra P, Patel NR, et al.Incidence trends and long-term survival analysis of sinonasal rhabdomyosarcoma[J]. Am J Otolaryngol, 2013, 34(6): 682-689. [19] Unsal AA, Chung SY, Unsal AB, et al.A population-based analysis of survival for sinonasal rhabdomyosarcoma[J]. Otolaryngol Head Neck Surg, 2017, 157(1): 142-149. [20] Siddiqui SH, Siddiqui E, Bavier RD, et al.Clinicopathologic traits and prognostic factors associated with pediatric sinonasal rhabdomyosarcoma[J]. Int Forum Allergy Rhinol, 2019, 9(4): 363-369. [21] Malempati S, Rodeberg DA, Donaldson SS, et al.Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group[J]. Cancer, 2011, 117(15): 3493-3501. [22] Häuβler SM, Stromberger C, Olze H, et al.Head and neck rhabdomyosarcoma in children: a 20-year retrospective study at a tertiary referral center[J]. J Cancer Res Clin Oncol, 2018, 144(2): 371-379. [23] Casey DL, Wolden SL.Rhabdomyosarcoma of the head and neck: a multimodal approach[J]. J Neurol Surg B Skull Base, 2018, 79(1): 58-64. [24] Stepan K, Konuthula N, Khan M, et al.Outcomes in adult sinonasal rhabdomyosarcoma[J]. Otolaryngol Head Neck Surg, 2017, 157(1): 135-141. [25] Reilly BK, Kim A, Pena MT, et al.Rhabdomyosarcoma of the head and neck in children: review and update[J]. Int J Pediatr Otorhinolaryngol, 2015, 79(9): 1477-1483. [26] Noujaim J, Thway K, Jones RL, et al.Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study[J]. Anticancer Res, 2015, 35(11): 6213-6217. [27] Ognjanovic S, Linabery AM, Charbonneau B, et al.Trends in childhood rhabdomyosarcoma incidence and survival in the united states, 1975-2005[J]. Cancer, 2009, 115(18): 4218-4226. |